Oncology

Chronic Lymphocytic Leukemia

Expert Roundtables Podcast: Expanding and Extending Chimeric Antigen Receptor T-Cell Therapy in Chronic Lymphocytic Leukemia

expert roundtables by Alessandra Ferrajoli, MD; Nitin Jain, MD; David G. Maloney, MD, PhD

Overview

<p>With the accelerated US Food and Drug Administration (FDA) approval of lisocabtagene maraleucel for chronic lymphocytic leukemia (CLL), CAR T-cell therapy now represents a new direction in the management of double-refractory CLL. Join expert panelists Alessandra Ferrajoli, MD, Nitin Jain, MD, and David G. Maloney, MD, PhD, as they discuss key considerations in the expansion and extension of CAR T-cell therapy for CLL.</p> <p> </p> <p><iframe title="Expert Perspectives® in Chronic Lymphocytic Leukemia 2025 Podcast" width="500" height="281" src="https://www.youtube.com/embed/Ofw_R-NnkpQ?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe></p>

References

Abbasi S, Totmaj MA, Abbasi M, et al. Chimeric antigen receptor T (CAR‐T) cells: novel cell therapy for hematological malignancies. Cancer Med. 2023;12(7):7844-7858. doi:10.1002/cam4.5551

Gill S, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6(21):5774-5785. Published correction appears in Blood Adv. 2023;7(21):6567.

Iovino L, Shadman M. CAR T-cell therapy for CLL: a new addition to our treatment toolbox? Clin Adv Hematol Oncol. 2023;21(3):134-141.

Jacobs R, Wierda W. Improving treatment options for patients with double refractory CLL. Cancers (Basel). 2025;17(3):430. doi:10.3390/cancers17030430

Wierda WG, Dorritie K, Gauthier J, et al. Lisocabtagene maraleucel (liso-cel) combined with ibrutinib (ibr) for patients (pts) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary results from the open-label, phase 1/2 TRANSCEND CLL 004 study [abstract 887] [session 642: Chronic lymphocytic leukemia: clinical and epidemiological: treating refractory disease-novel agents and quality-of-life]. Abstract presented at: 66th American Society of Hematology Annual Meeting and Exposition; December 7-10, 2024; San Diego, CA.

Zhao Z, Grégoire C, Oliveira B, Chung K, Melenhorst JJ. Challenges and opportunities of CAR T-cell therapies for CLL. Semin Hematol. 2023;60(1):25-33. doi:10.1053/j.seminhematol.2023.01.002

Zhu Y, Feng J, Wan R, Huang W. CAR T cell therapy: remedies of current challenges in design, injection, infiltration and working. Drug Des Devel Ther. 2023;17:1783-1792. doi:10.2147/dddt.S413348